Osimertinib

Osimertinib conferred a statistically significant and clinically meaningful improvement in OS compared with placebo among patients with early-stage EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer.

Two phase 3 trials evaluating pembrolizumab in combination with additional agents failed to meet their primary endpoints, according to the agent’s manufacturer.

In this edition, lobectomy alternatives show adverse event profiles; frequent CT scans not linked to better surgery outcomes; FDA approves adjuvant Keytruda, and more.

Drug-related pneumonitis occurred among 18% of patients receiving osimertinib for advanced epidermal growth factor receptor mutation-positive non-small cell lung cancer, according to study results published in CHEST.

In this video, Ravi Salgia, MD, PhD, highlighted two studies that investigated treatment for EGFR-mutated non-small cell lung cancer presented at ASCO Annual Meeting.

In this video, Erminia Massarelli, MD, PhD, MS, co-director of the lung cancer and thoracic oncology program, and associate professor in the department of medical oncology and therapeutics research at City of Hope Cancer Center in Duarte, California, discusses challenges in treating EGFR-mutated lung cancer.

In this video, Erminia Massarelli, MD, PhD, MS, co-director of the lung cancer and thoracic oncology program, and associate professor in the department of medical oncology and therapeutics research at City of Hope Cancer Center in Duarte, California, discusses treatment variations for rarer mutations such as EGFR exon 20 insertions.

In this video, Erminia Massarelli, MD, PhD, MS, co-director of the lung cancer and thoracic oncology program, and associate professor in the department of medical oncology and therapeutics research at City of Hope Cancer Center in Duarte, California, highlights treatment options for EGFR-mutated lung cancer.

In this video, Erminia Massarelli, MD, PhD, MS, co-director of the lung cancer and thoracic oncology program, and associate professor in the department of medical oncology and therapeutics research at City of Hope Cancer Center in Duarte, California, highlights disparities that exist in the treatment.

In this video, David R. Gandara, MD, spoke with Healio about discussions surrounding the ADAURA trial held at the 22nd annual International Lung Cancer Congress.